Europlasma (France) Performance
| ALEUP Stock | EUR 0.03 0 5.54% |
The firm shows a Beta (market volatility) of -3.84, which means a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Europlasma are expected to decrease by larger amounts. On the other hand, during market turmoil, Europlasma is expected to outperform it. At this point, Europlasma SA has a negative expected return of -2.52%. Please make sure to confirm Europlasma's skewness, as well as the relationship between the day median price and relative strength index , to decide if Europlasma SA performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Europlasma SA has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in December 2024. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors. ...more
| Begin Period Cash Flow | 4.2 M | |
| Total Cashflows From Investing Activities | -5.7 M |
Europlasma |
Europlasma Relative Risk vs. Return Landscape
If you would invest 24.00 in Europlasma SA on August 23, 2024 and sell it today you would lose (20.59) from holding Europlasma SA or give up 85.79% of portfolio value over 90 days. Europlasma SA is generating negative expected returns and assumes 10.2885% volatility on return distribution over the 90 days horizon. Simply put, 91% of stocks are less volatile than Europlasma, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Europlasma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Europlasma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Europlasma SA, and traders can use it to determine the average amount a Europlasma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2454
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ALEUP |
Estimated Market Risk
| 10.29 actual daily | 91 91% of assets are less volatile |
Expected Return
| -2.52 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.25 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Europlasma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Europlasma by adding Europlasma to a well-diversified portfolio.
Europlasma Fundamentals Growth
Europlasma Stock prices reflect investors' perceptions of the future prospects and financial health of Europlasma, and Europlasma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Europlasma Stock performance.
| Return On Equity | -1.1 | |||
| Return On Asset | -0.19 | |||
| Profit Margin | (0.27) % | |||
| Operating Margin | (0.84) % | |||
| Current Valuation | 6.76 M | |||
| Shares Outstanding | 5.59 M | |||
| Price To Earning | (0.93) X | |||
| Price To Book | 0.26 X | |||
| Price To Sales | 0.55 X | |||
| Revenue | 9.8 M | |||
| EBITDA | (4.02 M) | |||
| Cash And Equivalents | 3.92 M | |||
| Cash Per Share | 0.02 X | |||
| Total Debt | 2.92 M | |||
| Debt To Equity | 769.60 % | |||
| Book Value Per Share | 324.39 X | |||
| Cash Flow From Operations | (18.21 M) | |||
| Earnings Per Share | (4,055) X | |||
| Total Asset | 40.44 M | |||
| Retained Earnings | (57 M) | |||
| Current Asset | 20 M | |||
| Current Liabilities | 29 M | |||
About Europlasma Performance
Assessing Europlasma's fundamental ratios provides investors with valuable insights into Europlasma's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Europlasma is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Europlasma S.A., together with its subsidiaries, engages in plasma solutions, renewable energies, and asbestos waste treatment activities in France. Europlasma S.A. was founded in 1992 and is based in Pessac, France. EUROPLASMA operates under Waste Management classification in France and is traded on Paris Stock Exchange. It employs 116 people.Things to note about Europlasma SA performance evaluation
Checking the ongoing alerts about Europlasma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Europlasma SA help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Europlasma SA generated a negative expected return over the last 90 days | |
| Europlasma SA has high historical volatility and very poor performance | |
| Europlasma SA has some characteristics of a very speculative penny stock | |
| Europlasma SA has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations | |
| Europlasma SA has accumulated 2.92 M in total debt with debt to equity ratio (D/E) of 769.6, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Europlasma SA has a current ratio of 0.4, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Europlasma until it has trouble settling it off, either with new capital or with free cash flow. So, Europlasma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Europlasma SA sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Europlasma to invest in growth at high rates of return. When we think about Europlasma's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 9.8 M. Net Loss for the year was (12.67 M) with profit before overhead, payroll, taxes, and interest of 5.65 M. | |
| Europlasma SA has accumulated about 3.92 M in cash with (18.21 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02. |
- Analyzing Europlasma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Europlasma's stock is overvalued or undervalued compared to its peers.
- Examining Europlasma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Europlasma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Europlasma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Europlasma's stock. These opinions can provide insight into Europlasma's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Europlasma Stock Analysis
When running Europlasma's price analysis, check to measure Europlasma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Europlasma is operating at the current time. Most of Europlasma's value examination focuses on studying past and present price action to predict the probability of Europlasma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Europlasma's price. Additionally, you may evaluate how the addition of Europlasma to your portfolios can decrease your overall portfolio volatility.